Pulmonary Carcinosarcoma: A Surveillance, Epidemiology, and End Results (SEER) Analysis

Ersek, Jennifer L.; Symanowski, James T.; Han, Yimei; Howard, Alexander; Dumas, Kathryn; Ahrens, William A.; Kim, Elyssa; Kim, Edward S.

doi:10.1016/j.cllc.2019.07.001

Cited by 18 publications

(18 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recently, Ersek et al 6 reporting an analysis of the surveillance, epidemiology, and end results (SEER) for PC, found that surgical resection alone had better survival than other treatment modalities or combination therapies for this disease. Furthermore, another study, also using SEER database, sought to identify the prognostic factors and determine optimal treatment for PC 7 .…”

Section: Discussionmentioning

confidence: 99%

Stereotactic body radiation therapy for an octogenarian with pulmonary carcinosarcoma

et al. 2021

View full text Add to dashboard Cite

Pulmonary carcinosarcoma is a rare lung tumor accounting for <1% of primary lung cancers, characterized by biphasic components with both carcinomatous and sarcomatous mesenchymal features. This report describes a case of pulmonary carcinosarcoma in an octogenarian who was treated with stereotactic body radiation therapy (SBRT) and whose therapeutic response was sustained for 2 years. Along with other treatment modalities, SBRT might be considered for the treatment of medically inoperable localized stage pulmonary carcinosarcoma.

show abstract

Section: Discussionmentioning

confidence: 99%

Stereotactic body radiation therapy for an octogenarian with pulmonary carcinosarcoma

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Surgical resection is the optimal treatment modality for non-metastatic pulmonary carcinosarcoma. Case series exploring systemic treatment are limited, and the superiority of chemotherapy and radiotherapy to surgery remains controversial [1]. On the other hand, systemic treatment has been successful in part in patients who are not eligible for surgery.…”

Section: Discussionmentioning

confidence: 99%

“…However, they detected distant metastasis a few months later. Ersek et al [1] reported median survival duration of 20 months for patients who underwent surgery alone, 4 months for those who received radiotherapy, and 7 months for those treated with surgery and radiotherapy (p < 0.001). We prefer surgical treatment to systemic treatment for patients with PPC; because of the poorly differentiated and aggressive nature of these tumors, however, the prognosis is poor, with reported survival rates ranging from 20% to 57% [7,10,15,18,25].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Primary pulmonary carcinosarcomas: postoperative results and survival analysis

Doğru¹,

Sezen²,

Aker³

et al. 2020

Curr Thorac Surg

View full text Add to dashboard Cite

Background: In this study, we assessed the long-term results of 11 patients that we operated due to primary pulmonary carcinosarcoma in the light of literature. Materials and Methods: We analyzed 11 patients' data, who underwent lung resection, retrospectively between 2009-2018. The comorbidity score was calculated according to the modified Charlson Comorbidity Index (CCI). Results: Of the 11 patients in the study, 10 (90.9%) were male, one was female (%9.1), and the median age of the subjects was 59.18 ± 8.86. Nine of the patients (81.8%) underwent lobectomy, two of them (18.1%) underwent pneumonectomy. As a cellular type, 6 of them have squamous cell carcinoma, 5 of them have adenocarcinoma. Furthermore, as a sarcomatous component, we detected 6 of the patients have spindle cell sarcoma, 3 of them have chondrosarcoma, one of them has osteosarcoma. and one patient has angiosarcoma. Nine complications occur postoperatively in 5 patients (45.9%). The fiveyear survival rate was 36.4%. Patients who received adjuvant chemotherapy, the five-year survival rate was 50%, meanwhile, patients who did not receive adjuvant chemotherapy five-year survival rate was not detected (P = 0.006). If the patients have CCI score is two and below their five-year survival rate was 44.4%, meanwhile if the patients have CCI score is two and above their five-year survival rate was not detected (P = 0.018). Recurrence or metastasis was diagnosed in 7 patients (63.6%) postoperatively. The 5-year disease-free survival rate is 12.5%. Conclusions: Surgical resection is still the most effective treatment modality for these patients. Adjuvant therapy and comorbidity are detected most important factors that affect the survival rate.

show abstract

“…For pulmonary carcinosarcomas, surgery leads to a 5-year survival of approximately 30%, which is supported by a larger Surveillance, Epidemiology, and End Results (SEER) database study. 2 The SEER database study also suggests a far-worse prognosis in surgically unresectable disease, whereas Robinson and colleagues demonstrate a similar 5-year survival in nonsurgical patients treated with chemotherapy, radiotherapy, and/or immunotherapy. Surgical resection confers a comparable 5-year survival of nearly 30% for primary pulmonary sarcomas as well in comparison with 8% in unresectable disease, according to this study and another previous SEER database study.…”

mentioning

confidence: 99%

Commentary: Sarcomas and sarcomatoid tumors of the lung…not your average lung cancers

Sihag

2021

The Journal of Thoracic and Cardiovascular Surgery

View full text Add to dashboard Cite

show abstract

Pulmonary Carcinosarcoma: A Surveillance, Epidemiology, and End Results (SEER) Analysis

Cited by 18 publications

References 13 publications

Stereotactic body radiation therapy for an octogenarian with pulmonary carcinosarcoma

Stereotactic body radiation therapy for an octogenarian with pulmonary carcinosarcoma

Primary pulmonary carcinosarcomas: postoperative results and survival analysis

Commentary: Sarcomas and sarcomatoid tumors of the lung…not your average lung cancers

Contact Info

Product

Resources

About